Fig. 1From: Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitisFlow diagram showing the number (percentage) of children treated with HDM SLIT, pollen SLIT or pollen SCIT who completed the full 3 years, discontinued therapy prior to 3 years, or have ongoing therapyBack to article page